| Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study O Hansson, H Zetterberg, P Buchhave, E Londos, K Blennow, L Minthon The Lancet Neurology 5 (3), 228-234, 2006 | 2040 | 2006 |
| CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment N Mattsson, H Zetterberg, O Hansson, N Andreasen, L Parnetti, ... Jama 302 (4), 385-393, 2009 | 1367 | 2009 |
| Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease MM Zeron, O Hansson, N Chen, CL Wellington, BR Leavitt, P Brundin, ... Neuron 33 (6), 849-860, 2002 | 722 | 2002 |
| Cerebrospinal fluid levels ofβ-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia P Buchhave, L Minthon, H Zetterberg, ÅK Wallin, K Blennow, O Hansson Archives of general psychiatry 69 (1), 98-106, 2012 | 712 | 2012 |
| Plasma P-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia S Janelidze, N Mattsson, S Palmqvist, R Smith, TG Beach, GE Serrano, ... Nature medicine 26 (3), 379-386, 2020 | 619 | 2020 |
| Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts TK Karikari, TA Pascoal, NJ Ashton, S Janelidze, AL Benedet, ... The Lancet Neurology 19 (5), 422-433, 2020 | 602 | 2020 |
| Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity S Palmqvist, M Schöll, O Strandberg, N Mattsson, E Stomrud, H Zetterberg, ... Nature communications 8 (1), 1214, 2017 | 597 | 2017 |
| Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders S Palmqvist, S Janelidze, YT Quiroz, H Zetterberg, F Lopera, E Stomrud, ... Jama 324 (8), 772-781, 2020 | 579 | 2020 |
| Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity D Lindqvist, S Janelidze, P Hagell, S Erhardt, M Samuelsson, L Minthon, ... Biological psychiatry 66 (3), 287-292, 2009 | 529 | 2009 |
| Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people G De Meyer, F Shapiro, H Vanderstichele, E Vanmechelen, ... Archives of neurology 67 (8), 949-956, 2010 | 517 | 2010 |
| Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers GB Frisoni, M Boccardi, F Barkhof, K Blennow, S Cappa, K Chiotis, ... The Lancet Neurology 16 (8), 661-676, 2017 | 512 | 2017 |
| Amyloid biomarkers in Alzheimer's disease K Blennow, N Mattsson, M Schöll, O Hansson, H Zetterberg Trends in pharmacological sciences 36 (5), 297-309, 2015 | 486 | 2015 |
| Plasma β-amyloid in Alzheimer’s disease and vascular disease S Janelidze, E Stomrud, S Palmqvist, H Zetterberg, D Van Westen, ... Scientific reports 6 (1), 26801, 2016 | 477 | 2016 |
| Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis C Bridel, WN Van Wieringen, H Zetterberg, BM Tijms, CE Teunissen, ... JAMA neurology 76 (9), 1035-1048, 2019 | 443 | 2019 |
| Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders S Hall, A Öhrfelt, R Constantinescu, U Andreasson, Y Surova, F Bostrom, ... Archives of neurology 69 (11), 1445-1452, 2012 | 439 | 2012 |
| CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts O Hansson, J Seibyl, E Stomrud, H Zetterberg, JQ Trojanowski, T Bittner, ... Alzheimer's & dementia 14 (11), 1470-1481, 2018 | 433 | 2018 |
| Improving the survival of grafted dopaminergic neurons: a review over current approaches P Brundin, J Karlsson, M Emgård, GSK Schierle, O Hansson, Å Petersén, ... Cell transplantation 9 (2), 179-195, 2000 | 422 | 2000 |
| Plasma tau in Alzheimer disease N Mattsson, H Zetterberg, S Janelidze, PS Insel, U Andreasson, ... Neurology 87 (17), 1827-1835, 2016 | 405 | 2016 |
| CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease S Janelidze, H Zetterberg, N Mattsson, S Palmqvist, H Vanderstichele, ... Annals of clinical and translational neurology 3 (3), 154-165, 2016 | 386 | 2016 |
| Plasma tau levels in Alzheimer's disease H Zetterberg, D Wilson, U Andreasson, L Minthon, K Blennow, J Randall, ... Alzheimer's research & therapy 5 (2), 1-3, 2013 | 375 | 2013 |
Henrik ZetterbergSahlgrenskaVerified email at clinchem.gu.se
